• ½ðɳjs93252¼¯ÍÅ-¿ÆÑ§¼Ò·¢ÏÖÖÎÁƸ߼¶±ðÄÔ½ºÖÊÁöµÄÐÂ;¾¶
    2025-08-20 11:57:08

    ¿ÆÑ§¼Ò·¢Ã÷Ò½Öθ߼¶±ðÄÔ½ºÖÊÁöµÄз×Ó

    ÈÕÆÚ£º2023-05-10 À´Àú£º±¾Õ¾ ¹©¸å£º¹ú¼Ê»¥ÖúÓë»ùµØÆ½Ì¨´¦ ×÷ÕߣºÖÎÀíÔ± ÖÖ±ð£ºÒëÎÄ

    ÄÔ½ºÖÊÁöÊÇ×î¶à¼ûµÄÔ­·¢ÐÔÄÔÖ×Áö£¬·¢Ô´ÔÚÄêÒ¹ÄÔµÄÉñ¾­½ºÖÊϸ°û¡£¾­Óɹý³ÌÔö³¤µÍÃܶÈÖ¬ÂѰף¨LDL£©ÇéÊÆµ¨¹Ì´¼ÉãÈëµÄ´úÐ»ÖØ±à³Ì£¬ÊǰüÀ¨¸ß¼¶±ðÄÔ½ºÖÊÁö£¨HGG£©ÓÚÄÚµÄÖ×Áöϸ°ûÁ¬½á¿ìËÙÉú³¤µÄÒ»ÖÖ·½Ê½£¬ÊÇÒÔ£¬LDLÊÜÌ壨LDLR£©»òÕ߿ɳÉΪÖ×ÁöÒ½ÖθÉÉæ¸ÉÓëµÄDZÓڰбê¡£½üÆÚ£¬Åµ¶¡ººÄêҹѧÓë¶Å¿ËÄêҹѧµÄÑо¿Ö°Ô±·¢Ã÷£¬ºÜ¶àÉÄÑøHGGµÄѪ¹ÜÉϺ¬Óи̶߳ȵÄLDLR¡£Ñо¿½á¹û·¢±íÓÚ¡¶Pharmaceutics¡·ÆÚ¿¯£¬±êÌâΪ¡°Low-Density Lipoprotein Pathway Is a UbiquitousMetabolic Vulnerability in High Grade Glioma Amenable for NanotherapeuticDelivery¡±¡£ Ñо¿Ö°Ô±ÓÚÓÉ36Àý³ÉÈ˼°133Àý¶ù¿ÆHGG»¼ÕßµÄÖ×ÁöÑù±¾½¨ÔìµÄ¹¹Ôì΢ÕóÁÐÉÏ£¬ÔËÓÃÃâÒß¹¹Ô컯ѧ¾ÙÐмì²â£¬Ñо¿³É¹û×¢½â£¬ÓÚ³ÉÈ˼°¶ùͯÐÐÁв½¶ÓÖдæÓڹ㷺µÄLDLR±í´ï£¬ÌáÐÑLDLRÊÇËù·áÄêÁä¶ÎHGGµÄÓÐÓÃÒ½Öΰеã¡£Ëæºó£¬Ñо¿Ö°Ô±¾­Óɹý³ÌÃâÒßÓ«¹â¼¼ÄÜ£¬ÆÀ¹ÀÁËÈýÖÖ½ºÖÊĸϸ°ûÁö¾­³£Ê¹ÓõÄϸ°ûϵÖÐLDLRµÄ±í´ï£¬Ñо¿³É¹û×¢½â£¬Óë³ÉÈËGIN28ϸ°ûϵ±ÈÄ⣬¶ù¿ÆSF188¼°KNS42ϸ°ûϵ¾ß±¸Ïà¶ÔÓڽϸߵÄLDLR±í´ï³Ì¶È£¬ÌáÐÑÕâЩϸ°ûϵ¿ÉÒÔ½ðɳjs93252¼¯ÍÅ-ÓÃÔÚ²âÊÔLDL½éµ¼µÄÄÉÃ׿ÅÁ£/Ò©ÎïµÝËÍÄ£×Ó¡£ ¸ÃÑо¿ÎªÄÔ½ºÖÊÁöµÄÐÂÁÆ·¨¼°ÓÃÔÚÄÔ½ºÖÊÁöÒ½ÖεϝÁÆÒ©ÎïµÄµÝËÍÌṩÁËÐÂ˼Ð÷¡£ ×¢£º´ËÑо¿½á¹ûÕª×Ô¡¶Pharmaceutics¡·ÆÚ¿¯Ô­ÎÄÕ£¬ÎÄÕÂÄÚÈݲ»´ú±í±¾ÍøÕ¾²»Ñŵ㼰̬¶È£¬½ö¹©²Î¿¼¡£-½ðɳjs93252¼¯ÍÅ-



    ¸ü¶à²âÊÔÊý¾Ý¾´ÇëÆÚ´ý……